INCYTE CORPORATION Gain (Loss) on Repurchase of Debt Instrument
INCYTE CORPORATION (INCY) reported Gain (Loss) on Repurchase of Debt Instrument of -$17.93 million for the 12-month period ending 2013-12-31, per its 10-K filed 2016-02-12.
Discontinued › Income Statement › Other Income
us-gaap:GainLossOnRepurchaseOfDebtInstrument · last filed 2016-02-12
- INCYTE CORPORATION gain (loss) on repurchase of debt instrument for fiscal 2013 was -$17.93M.
| Period end | Gain (Loss) on Repurchase of Debt Instrument 12 month |
|---|---|
| 2013-12-31 | -$17.93M 10-K · filed 2016-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| IQVIA HOLDINGS INC. (IQV) | United States | $45.926B | 20.54 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B |